Whitehead Warren's Form 4 filing
Aptose Biosciences Inc. (APTO) · filed Jul 1, 2026
- Accession no.
- 0000912282-26-000900
- Filed
- Jul 1, 2026, 5:09 PM ET
- Trade date
- Jun 30, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 9 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Whitehead WarrenCIK 0001761449 | Other: FORMER DIRECTOR |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −33 | $1.72F2 | −$56.76 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −3,333 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −100,000 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −50,000 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −50,000 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −50,000 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −50,000 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −152,500 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −40,000 | $0.00 | $0 | 0 | Direct | |
| Jun 30, 2026 | Common Shares | DReturned to the companyDisposed | −53,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
Referenced by the price of 1 transaction in Table I.
Remarks
TOTAL OPTIONS AND OPTION EXERCISE PRICE SUBJECT TO ADJUSTMENT AS A RESULT OF THE ISSUER'S 1:30 REVERSE STOCK SPLIT ON 2/25/25 AND 1:15 REVERSE STOCK SPLIT ON 6/6/2023